HOME >> BIOLOGY >> NEWS
NIH funds first nationaL SNP genotyping center at Broad Institute

Bethesda, Md. -- The National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), announced today it will fund the first national center for high-throughput genotyping dedicated solely to large-scale SNP (single nucleotide polymorphism) analysis at the Eli and Edythe L. Broad Institute of MIT and Harvard University in Cambridge, Mass. A five-year cooperative agreement will provide over $14 million to create a high-capacity resource so that U.S. researchers can quickly and cost-effectively carry out large-scale studies of genetic variation in humans and animals to advance disease gene identification.

Research on genetic variation is aimed at improving the diagnosis and treatment of numerous diseases of humans that may have significant genetic components -- such as Type 1 diabetes, schizophrenia, and some types of cancer -- by identifying specific genetic markers, or genotypes, that are associated with particular diseases or responses to drug therapies. Studies examining genetic variation in animals such as mice and rats can identify genetic regions that, in humans, may contribute to complex diseases such as diabetes and hypertension.

"The tremendous potential of genetic research makes it critical that we develop this central resource so investigators around the country can access high capacity genotyping with the additional benefits of economies of scale, quality assurance and data sharing," said NCRR Division for Clinical Research Resources Director Anthony Hayward, M.D., Ph.D. "The demand for genotyping will grow exponentially as investigators prioritize potential targets for treatment and as members of afflicted families try to better estimate their risk for a particular condition."

Many diseases can be traced to inherited differences in each individual's genes. The most common type of variation in the human genome is the single nucleotide polymorphism, or SNP (pronounced "snip"). A SNP is a
'"/>


5-Oct-2004


Page: 1 2 3

Related biology news :

1. The Cancer Genome Atlas awards funds for technology development
2. NSF funds new Rutgers plant biomaterials initiative
3. NIH funds innovative alzheimers research initiated at UCSB
4. NSF funds biofertilizer research at Rutgers-Camden
5. ResearchChannel awards matching funds for video production
6. Research grant funds studies of climate change and reef ecosystems
7. NHGRI funds large-scale sequencing centers
8. NCI funds Einstein and U. Albany NanoCollege to make worlds smallest cancer detection device
9. Worcester Polytechnic Institute receives $2 million in federal funds for biomedical research centers
10. Columbia University Medical Center receives major new NIH Clinical Science investment funds
11. NIH funds Berkeley Lab research on defense against radiological attack

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIH funds first nationaL SNP genotyping center Broad Institute

(Date:6/15/2015)... DALLAS , June 16, 2015 ... Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), ... Worldwide Forecast to 2020" published by MarketsandMarkets, The Natural ... Billion at a CAGR of 18.4% for the forecast ... Tables and   46 F igures spread   ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
(Date:6/9/2015)... 9, 2015   MedNet Solutions , an innovative ... of clinical research, will be providing demonstrations of its ... the 2015 Drug Information Association (DIA) Annual Meeting in ... These presentations will include previews of many exciting new ... upcoming iMedNet 2015 Feature 1 Release. ...
Breaking Biology News(10 mins):Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... It ... brain injury (TBI) using single photon emission computed tomography (SPECT) according to ... The study, which examined over 20,000 brain scans and is believed to be the ...
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
Cached News: